Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients|
|Citation:||Expert Review of Hematology, 2011; 4(3):285-299|
|Publisher:||Expert Reviews Ltd|
|Devendra K Hiwase, David T Yeung and Deborah L White|
|Abstract:||Long-term follow-up of clinical studies has demonstrated the efficacy of imatinib therapy in newly diagnosed chronic phase-chronic myeloid leukemia patients (CML). However, recent updates of two separate randomized Phase III studies demonstrated higher complete cytogenetic and major molecular response rates with dasatinib and nilotinib compared with imatinib 400 mg/day. Hence, for newly diagnosed chronic phase-CML patients there are multiple treatment options, including standard-dose imatinib, high-dose imatinib, and combination therapy of imatinib and interferon, dasatinib and nilotinib. This article critically analyzes the current literature and provides guidelines for the management of newly diagnosed CML. Disease and therapy-related prognostic factors, which may aid in the selection of therapeutic strategies to enable optimal treatment outcomes, are discussed. In addition, we provide commentary on the therapeutic options for patients who fail imatinib therapy.|
|Keywords:||CML; dasatinib; imatinib; nilotinib; TKI|
|Rights:||© 2011 Expert Reviews Ltd.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.